Coegin Pharma has a solid IP portfolio of 20 patent families, including composition-of-matter patents, use patents, combination patents and formulation patents. The patent families in the table below have been filed in the United States, Europe, Canada, Japan, Australia and in other territories such as China, Hong Kong, Republic of Korea, India, Israel, New Zealand and Norway. The patent families expire from 2023 to 2037.
Selected patent families |
Granted |
Pending |
|
PCT/GB03/000364 |
AVX001 type ketones for the treatment of psoriasis AVX001 type ketones in a pharmaceutical composition |
Multiple granted United States patents |
|
PCT/2010/064687 |
Oxothiazole compounds and their use for the treatment of certain chronic inflammatory conditions |
Europe, United States, United States Continuation, Australia, Australia (divisional), Canada, China, China (Divisional), Japan, Republic of Korea, Republic of Korea (divisional), Hong Kong |
|
PCT/EP2010/003384 |
AVX001 type ketones for the treatment of glomerulonephritis |
Europe, Europe (Divisional), United States, Australia, Canada, Japan |
|
PCT/EP2014/051655 |
Oxothiazole compounds and their use in the treatment of chronic inflammatory disorders and proliferative disorders such as cancer |
Europe, United States, Australia, China, India, Japan |
Republic of Korea, Canada, China (divisional) |
PCT/EP2015/067836 |
Oxothiazole compounds and their use for the treatment of chronic inflammatory disorders and proliferative disorders such as cancer |
Europe, United States, Australia, Japan |
Canada, China, India, Republic of Korea, Hong Kong, United States (continuation) |
PCT/EP2015/061534 |
AVX001 type ketones for the treatment of skin cancer |
Europe, United States, Australia |
Canada, China, Republic of Korea |
PCT/EP2017/056022 |
AVX001 and AVX002 in combination with BEZ235 |
Australia |
Europe, United States, Canada, China, Japan, Republic of Korea, New Zealand, Hong Kong |
PCT/EP2017/056016 |
AVX235 and AVX420 in combination with BEZ235 |
Australia |
Europe, United States, Canada, China, Japan, New Zealand, Republic of Korea, Hong Kong |
PCT/EP2017/073951 |
Formulation comprising AVX001 type ketones and silicone |
Australia |
Europe, United States, Canada, China, India, Israel, Japan, New Zealand, Republic of Korea |
PCT/EP2017/078169 |
Oxothiazole compounds in combination with a secosteroid |
Australia |
Europe, United States, China, Israel, New Zealand |
PCT/EP2017/078162 |
Oxothiazole compounds in combination with a corticosteroid |
Australia |
Europe, United States, Canada, China, Israel, New Zealand |
PCT/EP2018/066028 |
AVX001 type ketones for the treatment of fibrotic diseases |
|
Europe, United States, Australia, Canada, China, Japan |
PCT/EP2019/060544 |
Oxothiazole compounds for the treatment of fibrotic diseases |
|
United States, China, Japan, Europe |